Stents Drug Eluting

Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable | January 17, 2017 | Dave Fornell

One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable...

Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting | November 02, 2016

November 2, 2016 — Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing...

Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting | November 01, 2016

November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...

News | Stents Drug Eluting | October 31, 2016

October 31, 2016 — Micell Technologies Inc. announced that it presented five-year clinical safety and efficacy...

EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD
Feature | Stents Drug Eluting | October 31, 2016

October 31, 2016 — A major international study has found that...

TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab | September 28, 2016

September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16...

Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016

August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L. Gore & Associates...

Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent
News | Stents Drug Eluting | June 03, 2016

June 3, 2016 — Biotronik announced results establishing non-inferiority of the Orsiro hybrid...

Biosensors' Biomatrix stent.

Feature | Stents | May 16, 2016

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables...

Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting | April 21, 2016

April 21, 2016 — Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its...

Absorb, bioresorbable stents
Feature | Stents Bioresorbable | April 13, 2016 | Dave Fornell

Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings...

Biotronik, BIOSCIENCE trial, Orsiro hybrid DES, drug-eluting stent, STEMI heart attack patients
News | Stents Drug Eluting | March 07, 2016

March 7, 2016 — Biotronik announced publication of results from the...

Medtronic, CE Mark, Resolute Onyx DES, drug-eluting stent, expanded sizes and indications
News | Stents Drug Eluting | February 02, 2016

February 2, 2016 — Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of...

News | Stents Drug Eluting | January 08, 2016

January 8, 2016 — In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient...

Blog | Cath Lab | November 05, 2015

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on...

Overlay Init